Entities / Company
Moderna.
American biotechnology company
- Reports this week
- 37
- Active events
- 17
- Connections
- 315
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
-
Moderna announced a collaboration with Merck KGaA regarding a personalized cancer vaccine platform.Well supported21 reports10 developments inside
-
Moderna presented vaccine results at the ESMO meeting in Madrid, with RBC Capital Markets covering the company.Some support1 report
-
Moderna and Merck released study results, while execution staff warned of potential issues during Christa Pike's execution attempt.Some support1 report
-
Moderna and Merck announced a partnership on their mRNA cancer vaccine trial, leading to analyst rating hikes.Well supported7 reports
-
Moderna and Merck are seeking FDA review for a novel cancer treatment, having co-led a Phase 3 mRNA vaccine trial.Well supported14 reports2 developments inside
-
Merck and Moderna funded an Australian-led clinical trial involving the University of Sydney.Some support1 report
-
Moderna and Iovance Biotherapeutics, alongside Dell, SanDisk, and MaxLinear, were noted among top stock gainers.Some support1 report
-
Allegations surfaced that FDA officials, including a safety data-mining expert, were involved in oversight failures regarding vaccine safety signals related to Moderna.Some support1 report2 developments inside
-
Johnson is investigating FDA records concerning adverse effects of Moderna vaccines.Some support3 reports
-
Biotech and pharmaceutical companies in Greater Boston are seeing strategic investments, talent movement, and antibody development advances.Some support1 report1 development inside
-
Moderna and BioNTech are recognized as leaders in the personalized cancer vaccine space.Some support1 report
-
Nasdaq added Moderna to its Nasdaq-100 index, and Moderna combined its vaccine with Merck's drug.Some support1 report
-
Moderna and Merck reported a landmark result from their melanoma study, while SanDisk and Dell were discussed in stock market analysis.Well supported4 reports1 development inside
-
Moderna's stock gains are being driven by FDA approval and the broader growth of AI businesses, as a Nasdaq constituent.Some support1 report
-
President Stephen Hoge sold shares of Moderna stock.Some support1 report
-
Moderna and Nvidia are being discussed in the context of stock market signals.Some support2 reports
-
Moderna, Pfizer, and Merck are part of a healthcare rotation story, with Moderna outperforming Pfizer in current stock gains.Some support2 reports
Earlier this month
-
India sought vaccines from Pfizer and Moderna during COVID-19, while Piyush Goyal emphasized the need for self-reliance.Some support2 reports
-
Multiple financial firms acquired, increased, or lessened stakes in Moderna shares, while the company president also sold shares.Some support1 report
-
Uğur Şahin and Özlem Türeci plan to leave BioNTech, while Moderna and Merck advance their combined vaccine study.Some support1 report
-
MarketBeat identified Micron Technology, Intel, and Moderna as Value stocks.Some support2 reports
-
Moderna and Pfizer are developing defenses against Lyme disease, while Tarsus offers a pill for tick threats, amid surveillance discussions.Some support2 reports
-
Moderna's stock performance is tracked on Nasdaq while Leerink Partners leads a Nasdaq IPO, amid oil price volatility and AI regulation tests.Some support1 report
-
The White House announced new tariffs on Canadian imports while noting integrated supply chains and drug price headwinds affecting the healthcare sector.Some support1 report2 developments inside
-
Both Moderna and Pfizer utilize mRNA technology for gene therapy.Some support1 report
-
Moderna and Merck conducted a study on mRNA vaccine while Rob Sand campaigned for Iowa governor, proposing plans to tackle cancer.Some support1 report
-
Analysts highlighted bullish calls and raised price targets for AbbVie, Moderna, and Eli Lilly amid sector optimism.Some support1 report
-
Australian researchers announced a global cancer vaccine breakthrough on August 20, 2026, which subsequently boosted Moderna's share price.Some support1 report
-
Major pharmaceutical companies face industry-wide pressure from patent cliffs and the need to streamline operations.Well supported3 reports1 development inside
-
Analyst downgrades and market challenges are impacting Moderna amid waning demand for COVID-19 vaccines, alongside pipeline successes.Some support2 reports
-
Positive test results were reported for Moderna's flu vaccine.Some support2 reports
-
Trump's policies, including tariffs and onshoring, are being discussed in the context of their potential benefits for AI stocks, with specific attention paid to Moderna's performance and guidance.Some support5 reports
-
Dolly Parton, whose roots are in rural Tennessee, donated $1 million to support COVID-19 research involving Moderna and Vanderbilt University.Well supported8 reports
-
Analysis suggests that both Moderna and Illumina stocks are currently overvalued.Some support1 report
One to three months ago
-
Insider trading filings made with the SEC regarding Moderna stock sales by President Stephen Hoge.Well supported7 reports
-
Moderna and Merck jointly developed and presented intismeran autogene therapy at the ESMO Congress in Madrid.Well supported4 reports
-
Moderna and Merck KGaA are working on personalized melanoma shots, with manufacturing challenges being discussed by Amy Walker.Some support2 reports1 development inside
-
Moderna and Novavax partnered with Merck KGaA on an individualized neoantigen program, driven by positive Phase 2b melanoma data.Some support3 reports
-
A market rally was observed in the biotech sector, driven by positive cancer vaccine news, causing Eli Lilly shares to rise.Well supported3 reports
-
Apple Inc., NetApp, and Moderna were mentioned together in a market context on September 13, 2026.Some support1 report
-
Simon Baker downgraded Moderna's stock rating from Neutral to Sell on September 3, 2026.Some support2 reports
-
MarketBeat provided average rating data for Moderna, while CLSA raised the rating and Jefferies reiterated a hold.Some support1 report
-
GlaxoSmithKline, Moderna, and Sinovac are leveraging the influenza vaccine market, with Phase 3 trials showing strong immune responses.Some support1 report2 developments inside
-
Trump administration pushes vaccine approval while FDA moves forward with Moderna vaccine, with Fauci noting incomplete protection.Well supported5 reports
-
Moderna's higher pricing is contrasted with GSK's and Pfizer's pricing in the context of a joint procurement agreement, which was deemed vital by Hadja Lahbib.Some support1 report
-
Moderna, Tempus, and Merck partnered on the INTerpath-001 trial, which focuses on indications that are covered by Medicare.Some support2 reports
-
Moderna and Merck announced a landmark moment in vaccine testing, alongside updates regarding personnel at Moderna and Columbia University.Some support1 report
-
Robert F. Kennedy Jr. collaborated on major cancer vaccine trials while criticizing mRNA technology and its potential funding.Some support2 reports
-
Moderna and DaVita are mentioned in the context of sector strength being driven by biotech innovation.Some support1 report
-
Dolly Parton contributed funding to COVID-19 vaccine research and her legacy was celebrated by the city of New York.Some support2 reports
-
Sally Kornbluth leads MIT's academic mission, while Noubar Afeyan connects Moderna and Flagship, with Maura Healey offering support for MIT innovation.Some support1 report
-
Pfizer, BioNTech, Merck KGaA, and Moderna announced joint developments regarding Comirnaty and a new cancer treatment.Some support1 report
-
Investor bets are shifting between the two biotech firms, Moderna and Exelixis, Inc.Some support1 report
-
Citigroup lifted its price objective on Moderna, while CLSA raised Moderna to an outperform rating.Some support1 report
-
Moderna and Merck are developing an experimental melanoma vaccine with partners, while concerns about AI models are impacting Gartner's business.Some support2 reports
-
Moderna combined its vaccine with Merck's Keytruda drug.Some support3 reports
-
The event covers Halliburton's expansion into Venezuelan oil fields, Moderna's clinical trial setbacks, and general corporate supply chain trends.Some support1 report
-
Suze Orman advised against concentration risk in Moderna.Some support2 reports
-
Moderna, Merck, and AbbVie are seeking new revenue streams to offset losses caused by patent expirations.Some support2 reports
-
Stella Parton donated $1 million to support COVID-19 research into mRNA vaccines.Some support1 report
No events began in the chosen period. Widen it, or reset.
What's reaching Moderna
Events traced to Moderna, step by step, newest firstAround Moderna this week
News at the entities that move Moderna most-
FDA StructuralWaters Corporation and LabCorp are partnering to expand access to FDA-approved HPV testing options.Moves Moderna
-
Dolly Parton TransactionalA tribute event honoring Dolly Parton featured performances by Carrie Underwood and Vince Gill, simulcast on Disney+ and shared by ABC.Moves Moderna
-
Merck OperationalMerck participates in a cancer vaccine study, with a researcher based at MD Anderson Cancer Center in Houston.Moves Moderna
-
Merck KGaA OperationalEvaxion will present clinical trial data at the ESMO Congress 2025 in Berlin, utilizing therapy from Merck Sharp & Dohme.Moves Moderna
-
Food and Drug Administration StructuralBiohaven filed an update on its NDA with the SEC, while the FDA indicated that advisory committee meetings were unnecessary.Moves Moderna
-
Centers for Disease Control and Prevention StructuralCDC research shows Massachusetts's firearm death rate, coinciding with Chapter 135 regulating guns in the state.Moves Moderna
Connections
The 40 strongest of 315, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Stéphane Bancel Structural
Stéphane Bancel holds the formal role of Chief Executive Officer of Moderna.
-
Dolly Parton Transactional
Dolly Parton donated $1 million to Moderna to support early COVID-19 vaccine research and development.
-
Merck Operational
Moderna and Merck are engaged in an ongoing partnership to jointly develop personalized mRNA cancer vaccines and combination therapies.
-
Merck KGaA Operational
Merck KGaA and Moderna maintain a strategic partnership focused on jointly developing and testing personalized mRNA cancer vaccines.
-
Lakshmi Srinivasan Structural
Lakshmi Srinivasan previously held a leadership role at Moderna.
-
Nasdaq Structural
Moderna is a constituent of the Nasdaq-100 index, and its stock performance influences the index's overall movement.
-
Pfizer Operational
Moderna and Pfizer are direct, high-stakes competitors in the biopharmaceutical market, vying for market share using mRNA technology across various vaccine and gene therapy platforms.
-
Robert Langer Structural
Robert Langer co-founded the biotech firm Moderna.
Show all 40 connections
-
Food and Drug Administration Structural
The FDA formally evaluates, regulates, and grants market access approvals for Moderna's products.
-
Noubar Afeyan Structural
Noubar Afeyan serves as a cofounder and board chair of Moderna.
-
Stephen Hoge Structural
Stephen Hoge serves as President of Moderna, overseeing its commercial, R&D, and manufacturing operations.
-
FDA Structural
The FDA formally regulates Moderna's pharmaceutical products, granting necessary approvals and setting guidelines for market entry and commercial viability.
-
CNBC Operational
CNBC actively covers Moderna's corporate announcements and stock movements, while Moderna utilizes CNBC's platform for major communications.
-
Centers for Disease Control and Prevention Structural
CDC regulates Moderna's vaccine eligibility and operations, and Moderna receives large government contracts.
-
Novavax Operational
Novavax and Moderna are direct competitors in the vaccine market, vying for market share and influencing each other's stock performance.
-
National Cancer Institute Structural
NCI provides funding for Moderna's mRNA trials and reports on the success of the company's research.
-
David Berman Structural
David Berman serves as the Chief Development Officer at Moderna.
-
Vanderbilt University Medical Center Structural
Vanderbilt University Medical Center provided foundational research, partnership, and funding integral to Moderna's vaccine development.
-
European Commission Structural
The European Commission formally approved the mCOMBRIAX vaccine and subsequently entered into a procurement contract with Moderna.
-
Mike Structural
Mike holds a formal governance role on the Moderna Board of Directors and Audit Committee.
-
Wade Davis Structural
Wade Davis serves as the senior vice president for digital at Moderna.
-
Walgreens Operational
Walgreens serves as a key distribution point, utilizing its locations to make Moderna vaccines available to the public.
-
Flagship Pioneering Structural
Flagship Pioneering is the founding entity responsible for the creation and structure of Moderna.
-
Donald Trump Structural
Moderna's operations and funding are directly influenced by the policy decisions and regulatory actions of Donald Trump's administration.
-
Coalition for Epidemic Preparedness Innovations Operational
Moderna and CEPI are engaged in a strategic collaboration focused on developing and testing advanced vaccine candidates.
-
MSD Operational
Moderna and MSD are actively collaborating on the joint development and clinical trials of autogene therapies and mRNA vaccines.
-
Michael McDonnell Structural
Michael McDonnell joined the Board of Directors of Moderna.
-
Health Canada Structural
Health Canada acts as the required regulatory body, providing authorization necessary for Moderna to conduct clinical studies in Canada.
-
Derrick Rossi Structural
Derrick Rossi is a co-founder of the biotechnology company Moderna.
-
Invesco Structural
Invesco holds Moderna as a significant investment position within its various ETFs.
-
Eli Lilly and Company Operational
The two companies are direct competitors operating within the high-risk biopharmaceutical and healthcare sectors.
-
Robert F. Kennedy Jr. Operational
RFK Jr.'s public challenges, lawsuits, and criticisms of mRNA technology actively influence Moderna's market perception and operational environment.
-
Department of Health & Human Services Structural
Moderna's research, funding, and operational projects are directly dependent on the grants, approvals, and funding decisions made by the Department of Health & Human Services.
-
Democratic Republic of the Congo Operational
Moderna is actively conducting Ebola vaccine trials and supplying vaccines in the Democratic Republic of the Congo.
-
Kennedy Operational
Kennedy criticized Moderna's mRNA technology and withdrew research grants for vaccine development.
-
AbbVie Operational
AbbVie and Moderna are major competitors operating within the high-risk biotechnology and pharmaceutical sectors.
-
Memorial Sloan Kettering Cancer Center Operational
Moderna and Memorial Sloan Kettering Cancer Center are actively partnering on personalized cancer vaccine trials and technology development.
-
North Carolina Transactional
North Carolina provided financial donations to support Moderna's vaccine development efforts.
-
Stella Parton Transactional
Stella Parton made a donation that supported Moderna's research into mRNA vaccines.
-
National Institutes of Health Operational
NIH and Moderna are engaged in a partnership to accelerate national cancer vaccine development.
History
Events by the month they beganOctober 2026
22 events- Moderna presented vaccine results at the ESMO meeting in Madrid, with RBC Capital Markets covering the company.
- Moderna and Merck released study results, while execution staff warned of potential issues during Christa Pike's execution attempt.
- Merck and Moderna funded an Australian-led clinical trial involving the University of Sydney.
- Moderna and Iovance Biotherapeutics, alongside Dell, SanDisk, and MaxLinear, were noted among top stock gainers.
- Johnson is investigating FDA records concerning adverse effects of Moderna vaccines.
- Biotech and pharmaceutical companies in Greater Boston are seeing strategic investments, talent movement, and antibody development advances.
- Moderna and BioNTech are recognized as leaders in the personalized cancer vaccine space.
- Nasdaq added Moderna to its Nasdaq-100 index, and Moderna combined its vaccine with Merck's drug.
- Moderna and Merck reported a landmark result from their melanoma study, while SanDisk and Dell were discussed in stock market analysis.
- Moderna's stock gains are being driven by FDA approval and the broader growth of AI businesses, as a Nasdaq constituent.
- President Stephen Hoge sold shares of Moderna stock.
- Moderna, Pfizer, and Merck are part of a healthcare rotation story, with Moderna outperforming Pfizer in current stock gains.
- India sought vaccines from Pfizer and Moderna during COVID-19, while Piyush Goyal emphasized the need for self-reliance.
- Multiple financial firms acquired, increased, or lessened stakes in Moderna shares, while the company president also sold shares.
- Uğur Şahin and Özlem Türeci plan to leave BioNTech, while Moderna and Merck advance their combined vaccine study.
- MarketBeat identified Micron Technology, Intel, and Moderna as Value stocks.
- Moderna and Pfizer are developing defenses against Lyme disease, while Tarsus offers a pill for tick threats, amid surveillance discussions.
- Moderna's stock performance is tracked on Nasdaq while Leerink Partners leads a Nasdaq IPO, amid oil price volatility and AI regulation tests.
- Both Moderna and Pfizer utilize mRNA technology for gene therapy.
- Moderna and Merck conducted a study on mRNA vaccine while Rob Sand campaigned for Iowa governor, proposing plans to tackle cancer.
- Analysts highlighted bullish calls and raised price targets for AbbVie, Moderna, and Eli Lilly amid sector optimism.
- Australian researchers announced a global cancer vaccine breakthrough on August 20, 2026, which subsequently boosted Moderna's share price.
September 2026
17 events- Analyst downgrades and market challenges are impacting Moderna amid waning demand for COVID-19 vaccines, alongside pipeline successes.
- Analysis suggests that both Moderna and Illumina stocks are currently overvalued.
- Moderna and Merck jointly developed and presented intismeran autogene therapy at the ESMO Congress in Madrid.
- Moderna and Merck KGaA are working on personalized melanoma shots, with manufacturing challenges being discussed by Amy Walker.
- Moderna and Novavax partnered with Merck KGaA on an individualized neoantigen program, driven by positive Phase 2b melanoma data.
- Apple Inc., NetApp, and Moderna were mentioned together in a market context on September 13, 2026.
- Simon Baker downgraded Moderna's stock rating from Neutral to Sell on September 3, 2026.
- MarketBeat provided average rating data for Moderna, while CLSA raised the rating and Jefferies reiterated a hold.
- Moderna's higher pricing is contrasted with GSK's and Pfizer's pricing in the context of a joint procurement agreement, which was deemed vital by Hadja Lahbib.
- Moderna and Merck announced a landmark moment in vaccine testing, alongside updates regarding personnel at Moderna and Columbia University.
- Moderna and DaVita are mentioned in the context of sector strength being driven by biotech innovation.
- Dolly Parton contributed funding to COVID-19 vaccine research and her legacy was celebrated by the city of New York.
- Sally Kornbluth leads MIT's academic mission, while Noubar Afeyan connects Moderna and Flagship, with Maura Healey offering support for MIT innovation.
- Pfizer, BioNTech, Merck KGaA, and Moderna announced joint developments regarding Comirnaty and a new cancer treatment.
- Investor bets are shifting between the two biotech firms, Moderna and Exelixis, Inc.
- Citigroup lifted its price objective on Moderna, while CLSA raised Moderna to an outperform rating.
- Moderna and Merck are developing an experimental melanoma vaccine with partners, while concerns about AI models are impacting Gartner's business.
August 2026
13 events- Moderna and Merck announced a partnership on their mRNA cancer vaccine trial, leading to analyst rating hikes.
- Moderna and Merck are seeking FDA review for a novel cancer treatment, having co-led a Phase 3 mRNA vaccine trial.
- Dolly Parton, whose roots are in rural Tennessee, donated $1 million to support COVID-19 research involving Moderna and Vanderbilt University.
- Insider trading filings made with the SEC regarding Moderna stock sales by President Stephen Hoge.
- A market rally was observed in the biotech sector, driven by positive cancer vaccine news, causing Eli Lilly shares to rise.
- Trump administration pushes vaccine approval while FDA moves forward with Moderna vaccine, with Fauci noting incomplete protection.
- Moderna, Tempus, and Merck partnered on the INTerpath-001 trial, which focuses on indications that are covered by Medicare.
- Robert F. Kennedy Jr. collaborated on major cancer vaccine trials while criticizing mRNA technology and its potential funding.
- Moderna combined its vaccine with Merck's Keytruda drug.
- The event covers Halliburton's expansion into Venezuelan oil fields, Moderna's clinical trial setbacks, and general corporate supply chain trends.
- Suze Orman advised against concentration risk in Moderna.
- Moderna, Merck, and AbbVie are seeking new revenue streams to offset losses caused by patent expirations.
- Stella Parton donated $1 million to support COVID-19 research into mRNA vaccines.
Show 1 earlier month
June 2026
8 events- Moderna announced a collaboration with Merck KGaA regarding a personalized cancer vaccine platform.
- Allegations surfaced that FDA officials, including a safety data-mining expert, were involved in oversight failures regarding vaccine safety signals related to Moderna.
- Moderna and Nvidia are being discussed in the context of stock market signals.
- The White House announced new tariffs on Canadian imports while noting integrated supply chains and drug price headwinds affecting the healthcare sector.
- Major pharmaceutical companies face industry-wide pressure from patent cliffs and the need to streamline operations.
- Positive test results were reported for Moderna's flu vaccine.
- Trump's policies, including tariffs and onshoring, are being discussed in the context of their potential benefits for AI stocks, with specific attention paid to Moderna's performance and guidance.
- GlaxoSmithKline, Moderna, and Sinovac are leveraging the influenza vaccine market, with Phase 3 trials showing strong immune responses.